## **Core Concept**
The escape phenomenon in mineralocorticoid excess refers to the body's ability to counteract the sodium-retaining and potassium-losing effects of excessive mineralocorticoids. This phenomenon involves various mechanisms to normalize blood pressure and electrolyte balance despite the continued presence of high levels of mineralocorticoids.

## **Why the Correct Answer is Right**
The correct answer, **C. Increased ANP (Atrial Natriuretic Peptide)**, is right because in the context of mineralocorticoid excess, the body experiences volume expansion and hypertension. This volume expansion increases atrial stretch, which in turn stimulates the release of ANP. ANP promotes natriuresis (sodium excretion) and kaliuresis (potassium excretion), helping to mitigate the sodium-retaining effects of mineralocorticoids. This mechanism is a key part of the escape phenomenon, allowing the body to escape from the sodium-retaining effects of mineralocorticoid excess.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Decreased sympathetic tone does play a role in various physiological responses, but it is not the primary mechanism behind the escape phenomenon in mineralocorticoid excess.
- **Option B:** While changes in renal prostaglandins can influence renal function, they are not the primary reason for the escape phenomenon in this context.
- **Option D:** Increased ADH (Antidiuretic Hormone) would actually worsen water retention and is not a mechanism for escaping the effects of mineralocorticoid excess.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that the escape phenomenon is crucial for understanding how patients with primary aldosteronism (a condition of mineralocorticoid excess) may not always present with severe hypokalemia or marked volume overload, despite high levels of aldosterone. The body's ability to escape from the sodium-retaining effects of aldosterone helps to mitigate some of the clinical manifestations.

## **Correct Answer: C. Increased ANP (Atrial Natriuretic Peptide)**